SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 155 filers reported holding SAGE THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 1.15 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,564,970 | -55.8% | 76,044 | +1.0% | 0.00% | -50.0% |
Q2 2023 | $3,538,725 | +98088.8% | 75,260 | -12.4% | 0.00% | 0.0% |
Q1 2023 | $3,604 | +12.4% | 85,893 | +2.2% | 0.00% | 0.0% |
Q4 2022 | $3,205 | -99.9% | 84,034 | +1.7% | 0.00% | -20.0% |
Q3 2022 | $3,234,000 | +29.7% | 82,594 | +7.0% | 0.01% | +25.0% |
Q2 2022 | $2,493,000 | +77.9% | 77,189 | +82.4% | 0.00% | +100.0% |
Q1 2022 | $1,401,000 | -31.2% | 42,324 | -11.5% | 0.00% | 0.0% |
Q4 2021 | $2,035,000 | -3.8% | 47,848 | +0.2% | 0.00% | -33.3% |
Q3 2021 | $2,116,000 | -28.4% | 47,756 | -8.2% | 0.00% | -25.0% |
Q2 2021 | $2,956,000 | -28.8% | 52,041 | -6.1% | 0.00% | -33.3% |
Q1 2021 | $4,150,000 | -16.7% | 55,445 | -3.7% | 0.01% | -14.3% |
Q4 2020 | $4,981,000 | +44.1% | 57,575 | +1.8% | 0.01% | +40.0% |
Q3 2020 | $3,457,000 | +44.4% | 56,565 | -1.8% | 0.01% | +25.0% |
Q2 2020 | $2,394,000 | +62.7% | 57,575 | +12.4% | 0.00% | +33.3% |
Q1 2020 | $1,471,000 | -60.8% | 51,224 | -1.4% | 0.00% | -50.0% |
Q4 2019 | $3,750,000 | -47.3% | 51,940 | +2.3% | 0.01% | -53.8% |
Q3 2019 | $7,122,000 | -23.7% | 50,768 | -0.5% | 0.01% | -27.8% |
Q2 2019 | $9,340,000 | +20.6% | 51,012 | +4.8% | 0.02% | +20.0% |
Q1 2019 | $7,743,000 | +72.3% | 48,684 | +3.8% | 0.02% | +50.0% |
Q4 2018 | $4,493,000 | -34.2% | 46,907 | -3.0% | 0.01% | -23.1% |
Q3 2018 | $6,828,000 | -11.5% | 48,337 | -1.9% | 0.01% | -18.8% |
Q2 2018 | $7,711,000 | +16.9% | 49,262 | +20.3% | 0.02% | +14.3% |
Q1 2018 | $6,597,000 | +4.0% | 40,955 | +6.3% | 0.01% | +7.7% |
Q4 2017 | $6,346,000 | +140.4% | 38,526 | -9.1% | 0.01% | +116.7% |
Q3 2017 | $2,640,000 | -19.4% | 42,371 | +3.0% | 0.01% | -14.3% |
Q2 2017 | $3,276,000 | +22.7% | 41,138 | +9.4% | 0.01% | +16.7% |
Q1 2017 | $2,671,000 | +44.8% | 37,587 | +4.0% | 0.01% | +20.0% |
Q4 2016 | $1,845,000 | +38.3% | 36,129 | +24.8% | 0.01% | +25.0% |
Q3 2016 | $1,334,000 | +82.0% | 28,959 | +19.0% | 0.00% | +100.0% |
Q2 2016 | $733,000 | +49.6% | 24,337 | +59.2% | 0.00% | 0.0% |
Q1 2016 | $490,000 | -37.9% | 15,290 | +13.0% | 0.00% | -33.3% |
Q4 2015 | $789,000 | +53.5% | 13,535 | +11.4% | 0.00% | +50.0% |
Q3 2015 | $514,000 | -39.4% | 12,155 | +4.7% | 0.00% | -33.3% |
Q2 2015 | $848,000 | – | 11,610 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |